Axogen, Inc.
A maker of surgical products that repair damaged peripheral nerves, Axogen's lineup includes the Avance Nerve Graft (processed human nerve tissue) and the Axoguard line of porcine-based connectors, protectors, and caps used by surgeons to restore feeling and movement. The business grew out of technology licensed from the University of Florida and took its current form after a 2011 merger, with the FDA approving Avance as a licensed biologic in 2025. A neat quirk: before Avance, the standard repair often meant cutting a healthy nerve from elsewhere in the patient's own body, so the fix created a new injury.
Granted 94.2K · Sold 25.9K
Granted 59.5K · Sold 45.3K
Sold 3.9K
Granted 73.2K · Sold 12.2K
Granted 89.2K · Sold 30.3K
Granted 150.0K · Sold 86.5K
Granted 67.5K · Sold 22.5K
Granted 14.2K
Granted 112.2K · Sold 132.5K
Granted 18.9K · Sold 21.4K
Granted 70.6K · Sold 63.0K
Granted 45.6K · Sold 56.4K
Granted 39.3K · Sold 25.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| DeVinney Erick WayneChief Innovation Officer · 11 transactions | +20.7% | 262.8K | 94.2K | — | 25.9K |
| Wendell Amy McBrideDirector · 9 transactions | +15.1% | 108.0K | 59.5K | — | 45.3K |
| Quackenbush DorisSales VP · 1 transaction | — | 96.3K | — | — | 3.9K |
| Kemp JensChief Marketing Officer · 6 transactions | +161.7% | 72.5K | 73.2K | — | 12.2K |
| Hartley Lindsey MarieCFO · 18 transactions | +213.8% | 65.1K | 89.2K | — | 30.3K |
| Dale Michael DChief Executive Officer · 3 transactions | — | 63.5K | 150.0K | — | 86.5K |
| Began Marc AEVP & General Counsel · 7 transactions | +198.4% | 54.6K | 67.5K | — | 22.5K |
| Levine Alan MDirector · 1 transaction | +38.5% | 50.9K | 14.2K | — | — |
| Burke William P. Mr.Director · 21 transactions | — | 38.7K | 112.2K | — | 132.5K |
| Thomas PaulDirector · 2 transactions | -7.2% | 32.4K | 18.9K | — | 21.4K |
| Weiler Kathy JohnsonDirector · 8 transactions | +115% | 14.2K | 70.6K | — | 63.0K |
| Johnson JohnDirector · 9 transactions | -43.3% | 14.2K | 45.6K | — | 56.4K |
| Tyndall Joseph A.Director · 5 transactions | -47.5% | 14.2K | 39.3K | — | 25.1K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -524.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.